Evaluating heart function in sepsis using advanced imaging techniques
The Diagnostic and Prognostic Value of Speckle Tracking Imaging in Septic Cardiomyopathy: a Prospective Cohort Study
Shanghai Zhongshan Hospital · NCT05624619
This study is testing a new imaging technique to see if it can help doctors better understand heart function in patients with sepsis and predict their outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Shanghai Zhongshan Hospital (other) |
| Locations | 1 site (Shanghai) |
| Trial ID | NCT05624619 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the role of speckle tracking imaging (STI), particularly the tissue motion analysis derived (TMAD) method, in assessing left ventricular function in patients diagnosed with sepsis. The researchers will evaluate whether TMAD can effectively differentiate septic-induced cardiomyopathy (SICM) and provide predictive insights regarding patient outcomes. By gathering evidence-based data, the study seeks to enhance clinical applications of STI technology in managing sepsis-related cardiac dysfunction.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with sepsis according to the Sepsis 3.0 criteria.
Not a fit: Patients with a history of organic heart disease, heart failure, or those with cardiac implanted devices will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the diagnosis and management of cardiac dysfunction in sepsis patients, leading to better patient outcomes.
How similar studies have performed: While the use of speckle tracking imaging is established in other cardiac conditions, this specific application in septic cardiomyopathy is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients who are diagnosed as sepsis according to sepsis 3.0 criteria Exclusion Criteria: * patients with history of organic heart disease; * patients with history of heart failure * holder of cardiac implanted device; * patients with history of atrial fibrillation; * refusal to participate in the study
Where this trial is running
Shanghai
- 180 Fenglin Road — Shanghai, China (RECRUITING)
Study contacts
- Principal investigator: Jieqiong Song — Fudan University
- Study coordinator: Jieqiong Song
- Email: song.jieqiong@zs-hospital.sh.cn
- Phone: 13917056745
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Sepsis, Cardiomyopathies, Echocardiography